AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. AIM
  4. [EFFECT] AIM ImmunoTech Inc. SEC Filing

[EFFECT] AIM ImmunoTech Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: July 3, 2025 4:00 P.M.
Form: S-3
CIK: 0000946644
Company Name: AIM ImmunoTech Inc.
File Number: 333-286319

Source:

Stock AIM logo
Aim Immunotech

NYSE:AIM

AIM Rankings

#6227 Ranked by Market Cap
N/A Ranked by Dividends

AIM Latest News

Sep 4, 2025
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
Aug 21, 2025
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Aug 15, 2025
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 14, 2025
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Aug 6, 2025
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM Latest SEC Filings

Jul 31, 2025
[8-K] AIM ImmunoTech Inc. Reports Material Event
Jul 30, 2025
[424B5] AIM ImmunoTech Inc. Prospectus Supplement (Debt Securities)
Jul 28, 2025
[8-K] AIM ImmunoTech Inc. Reports Material Event
Jul 22, 2025
[S-1/A] AIM ImmunoTech Inc. Amends IPO Registration Statement
Jul 21, 2025
[Form 4] AIM ImmunoTech Inc. Insider Trading Activity

AIM Stock Data

6.61M
2.62M
3.42%
1.72%
2.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
OCALA